| 摘要 |
The present invention relates to a method for early prediction of a prostate cancer patient's response to hormonal treatment. In one embodiment, the method of the present invention involves assaying a body fluid, such as plasma or serum, from a prostate cancer patient for the presence of elevated levels of chromogranin A (CgA). Elevated levels of CgA may indicate neuroendocrine differentiation of cells within the prostate tumor, and may require altering the patient's treatment. In a further embodiment of the method of the present invention, periodic assays for CgA are conducted for a patient undergoing hormonal treatment for prostate cancer. The results of these assays are correlated to determine if the patient's levels of CgA are high (greater than 100 ng/mL) or increasing. Such assays may also be carried out in conjunction with assays for total prostate specific antigen (tPSA).
|
